SCHEMBL8095680

SCHEMBL8095680

Cc1cc(OC2CCN(Cc3ccccc3F)CC2)c2cccc(F)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.46
DCPS Q96C86 2/20 0.43
KCNH2 Q12809 2/20 0.43
SCN5A Q14524 2/20 0.43
SCN9A Q15858 2/20 0.43
SCN1A P35498 2/20 0.43
SCN8A Q9UQD0 2/20 0.43
ATM Q13315 1/20 0.42
PHGDH O43175 1/20 0.42
ACHE P22303 3/20 0.41
PDE2A O00408 1/20 0.41
CYP2D6 P10635 1/20 0.41
BCHE P06276 1/20 0.41
EHMT2 Q96KQ7 1/20 0.41
OPRK1 P41145 1/20 0.41
ALDH1A1 P00352 3/20 0.40
HTR2C P28335 1/20 0.40
HTR7 P34969 1/20 0.40
HTR2B P41595 1/20 0.40
HTR3A P46098 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5526683 0.90 SCN1A (0.50) KCNH2SCN5ASCN9ASCN1ASCN8A
SCHEMBL8088026 0.90 HTR2C (0.40) PDE4BDCPSSCN1ASCN8AACHE
SCHEMBL8095861 0.89 KCNH2 (0.41) KCNH2SCN5ASCN9ASCN1ASCN8A
SCHEMBL8094095 0.89 GRIN1 (0.40) PDE4BKCNH2SCN5ASCN9ASCN1A
SCHEMBL8104328 0.89 PDE2A (0.43) PDE4BSCN1ASCN8APDE2AALDH1A1
SCHEMBL8100325 0.89 JAK2 (0.39) PDE4BDCPSKCNH2SCN5ASCN9A
SCHEMBL8091662 0.89 HRH1 (0.47) KCNH2SCN1ASCN8AALDH1A1KMT2A
SCHEMBL5529538 0.88 PDE4B (0.46) PDE4BDCPSKCNH2SCN5ASCN9A
SCHEMBL13945393 0.88 ADRB2 (0.51) PDE4BPDE2AALDH1A1KDM4EKMT2A
SCHEMBL8102279 0.87 HTR2B (0.42) PDE4BKCNH2SCN5ASCN9ASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 PDE4B 1060/4885DCPS 2586/4885KCNH2 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.